SCM
MGNX icon

Silvant Capital Management’s MacroGenics MGNX Stock Holding History

Silvant Capital Management’s Portfolio MGNX Stock Details MGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-4,637
Closed -$59K – 339
2019
Q3 		$59K Hold
4,637
– – 0.01% 253
2019
Q2 		$79K Buy
+4,637
New +$79.6K 0.01% 249

Other funds holding MGNX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Silvant Capital Management's MGNX Position: Q4 2019 in Review

Silvant Capital Management sold out of MacroGenics (MGNX) in Q4 2019, closing a stake of 4,637 shares — an estimated $59K sold.

Silvant Capital Management first reported a position in MGNX in Q2 2019 and held it in 2 quarters. The position peaked at $79K in Q2 2019. 124 funds tracked by Wall St. Rank hold MGNX as of Q4 2019.

  • Silvant Capital Management reported no remaining MacroGenics position as of Q4 2019 after selling out during the quarter.
  • Silvant Capital Management sold 4,637 MacroGenics shares in Q4 2019, an estimated $59K.
  • Silvant Capital Management first reported a position in MacroGenics in Q2 2019 and held it in 2 quarters.
  • Silvant Capital Management's MacroGenics position peaked at $79K in Q2 2019.
  • 124 funds tracked by Wall St. Rank held MacroGenics as of Q4 2019.

Based on Silvant Capital Management's 13F filing for Q4 2019, filed 10 Feb 2020.